Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 5,800 employees.

The major stock indices are all lower at midday on Friday and hopes for a winning week -- after four weeks of losses -- appear to be fading. Ongoing uncertainty about the status and the impact of tariffs and worries about a potentially slowing economy seem more powerful at the moment than any effort to 'buy the dip.' Not helping the cause today are cautious outlooks from the likes of FedEx (possible weakening economy), Nike (possible weary consumer), and Lennar (possible slowing housing market).

This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.